Berlin Conference on Life Sciences 2018: Programme

Programme of the “11th Berlin Conference on Life Sciences – Novel Antimicrobials and AMR Diagnostics”

8:00	Registration
Opening Session
8:45	Introduction
8:50	Welcome address Frank Emmrich, Director Fraunhofer Institute for Cell Therapy and Immunology IZI, GER
9:00	Setting the scene Marc Gitzinger, CEO BioVersys AG, CH and Vice-President, BEAM Alliance PDF
Plenary Session
9:10	Keynotes Addressing drug-resistant infections: a global and collaborative endeavour Jean-Pierre Paccaud, Director Business Development, Global Antibiotics Research and Development Partnership (GARDP) Feeding the AMR pipeline through innovation – challenges and solutions for European SMEs Mark Jones, Head of Project Management, Basilea Pharmaceutica Ltd, CH; Secretary, BEAM Alliance
	Replenishing and Enabling the Pipeline for Anti-Infective Resistance Aleks Engel, Partner Novo Seeds and Director, Novo Holdings Repair Impact Fund, DK George E Griffin, Chair of fund SAB, Novo Holdings Repair Impact Fund and Emeritus Professor of Infectious Diseases and Medicine, St George’s, University of London, UK
	The challenge of bringing successful AMR diagnostics to the clinic Jorge Villacian, Chief Medical Officer, Janssen Diagnostics, Janssen Pharmaceutical R&D, Johnson & Johnson, BE
10:30 Coffee break with posters & exhibition
Session 1 Market access in the era of AMR - from idea to product		Session 2 From basic research to market - recent academic anti-infective and diagnostics innovations
11:00	The patent perspective: How to protect IP in a field of multiple public, private and public/private collaborations? Markus Engelhard, Partner, Boehmert & Boehmert, GER	11:00	Introduction: The value of academic research in AMR innovations Herman Goossens, Head of LMM, Vaccine & Infectous Disease Institute, University of Antwerp, BE PDF
	Handling innovative approaches in traditional clinical settings & new routes for efficacy evaluation Introduction: A new breakthrough class of Gram-negative antibiotics Glenn Dale, Head of Antibiotic Research and Early Development, Polyphor Ltd, CH Panel discussion: "Efficacy evaluation for novel antimicrobial approaches: current challenges and new routes" - Guennaëlle Dieppois, Senior Scientist, Debiopharm, CH - Johan Mouton, Chair, National AST Committee, EUCAST - Nicolas Tesse, Scientific Director, Neteos Groupe, FR - Glenn Dale, Head of Early Development, Polyphor Ltd, CH - Jean-Pierre Paccaud, Director Business Development, GARDP		Tackling AMR via innovative natural products Rolf Müller, Managing Director, Helmholtz Institute for Pharmaceutical Research Saarland & Coordinator "Novel Antibiotics", German Center for Infection Research (DZIF), GER PDF First clinical results of cold plasma treated chronic infected wounds Kai Masur, Principal Investigator, Leibniz Institute for Plasma Science and Technology, GER Identification of novel antimicrobials using cell-free systems Stefan Kubick, Head of Department of Cell-free and Cell-based Bioproduction, Fraunhofer Institute for Cell Therapy and Immunology IZI, GER
	Accelerating diagnostics use to prevent AMR on a global level Catharina Boehme, CEO, FIND Diagnostics		Antibiotics research at the Institut Pasteur in Paris and in the Institut Pasteur International Network Philippe Glaser, Institut Pasteur, F
	Sustainable economic models to revitalise antibiotic development - lessons learned from DRIVE AB Christine Årdal, Senior Advisor, Norwegian Institute of Public Health, NO		Diagnostic tools to distinguish between bacterial and viral infections to reduce antibiotic abuse Per Venge, Professor, Uppsala University, SE
	Panel discussion: How to bring AMR innovation to the market? - Panel chair: Christine Årdal, Senior Advisor, Norwegian Institute of Public Health, NO - Anders Karlén, Leader of the managing entity at ENABLE, & Professor, Uppsala University, SE - Ghada Zoubiane, Science Lead of the Drug Resistant Infection Program, Wellcome Trust, UK - Jorge Villacian, Chief Medical Officer, Janssen Diagnostics, Janssen Pharmaceutical R&D, Johnson & Johnson, BE		Rapid Diagnostics - From Barriers to Solutions for AMR Till Bachmann, Deputy Head of Division of Infection and Pathway Medicine, University of Edinburgh, UK
12:50	Lunch break with posters & exhibition
Session 3 Technology highlights and challenges - novel antimicrobials		Session 4 Technology highlights and challenges – diagnostics
13:50	Introduction: The value of SMEs in AMR innovations Marie Petit, Coordinator, BEAM Alliance	13:50	Introduction to the session Frauke Hein, CBO, AdrenoMed AG, DE Platforms, biomarkers, data: an industry perspective on molecular microbiology Achim Plum, CBO, Curetis N.V., GER
	Priority Setting for R&D of New Antibiotics – the WHO Perspective Sarah Paulin, Technical Officer, Innovation, Access and Use Unit, Essential Medicines and Health Products, World Health Organization PDF		Bringing photonics to the clinic: concept for an user-open center for photonics in infection research Jürgen Popp, Managing Board, InfectoGnostics Research Campus & Scientific Director, Leibniz Institute for Photonic Technologies, GER
	Fostering investment in AMR innovation - the UNCTAD World Investment Forum 2018 Christoph Spennemann, Legal Officer and Officer-in-Charge, Intellectual Property Unit, Division on Investment and Enterprise UNCTAD PDF		Rapid tests to detect antibiotic resistance Bruce Savage CEO, GFC Diagnostics, UK PPX
	The need for coordination: the Global AMR R&D Hub Andrea Spelberg, Head of Division 616 - Global Health Unit, Federal Ministry of Education and Research, GER		Development of diagnostics for antimicrobial resistance – a company perspective Ralf Ehricht, Senior Principal Scientist Feasibility Studies, Abbott (former Alere Technologies GmbH), GER
	Insights into the development of anti-infective therapies in AMR dedicated SMEs in Europe: The development of a synthetic branched peptide for fighting multi-resistant Gram-negative bacteria Alessandro Pini, Founder & President of the Executive Board, SetLance srl PDF Six birds by two stones - the development of ASN100, a monoclonal antibody product candidate targeting Staphylococcus aureus Zoltán Magyarics, Director of Early Clinical Development, Arsanis PDF Artilysin® - an intelligent platform technology to combat MDR pathogens Martin Grießl, Deputy Director R&D, Head of Protein Design, Lysando AG, GER PDF		Ultra-fast Laser PCR Technology for medical diagnostics Lars Ullerich, Managing Director, GNA Biosolutions, GER
	Leveraging technology to spur antibiotic discovery Mariana Vaschetto, Collaborative Drug Discovery Inc., UK PDF		Concept ≠ Technology ≠ Product. What it takes to create an actionable Dx in the fight against AMR Kfir Oved, CTO & Co-Founder, MeMed Diagnostics Ltd, ISR
15:30	Coffee break with posters & exhibition
Closing session Financing and funding opportunities for SMEs and start-ups in the AMR field
16:00	Start-up pitch Ajay Mistry, CEO & Co-Founder, Oppilotech, UK Juan José Infante Viñolo, CEO & Co-Founder, Vaxdyn, ES PDF Andreas A. Bastian, CEO & Co-Founder, AGILeBiotics B.V., NL Daniel Mark, CEO & Co-Founder, SPINDIAG GmbH, GER PDF Alexander Belcredi, CEO & Co-Founder, PhagoMed, AUT PDF Danuta Cichocka, CEO & Co-Founder, Resistell, Resistell, CH PDF Antonio Ornelas Soares, FASTinov, PT
	Investor talk: Which business models are worth to invest? Henri-François Boedt, European Investment Bank Kevin Outtersson, Executive Director, CARB-X, US Beat Steffen, Principal, Novartis Venture Fund, CH Aleks Engel, Partner Novo Seeds and Director, Novo Holdings Repair Impact Fund, DK Emmanuelle Coutanceau, Partner at Novo Seeds, Novo Holdings A/S, DK Peter Jackson, Executive Director, ARMC, UK
	Interactive Marketplace AMRC CARB-X GARDP EIB ENABLE Netherlands Antibiotic Development Platform Wellcome Trust Novo Holdings Repair Impact Fund
	Start-up ceremony
17:30	Networking & reception